Quarterly ResultMay 4, 2026, 04:08 PM
Inspire Medical Q1 Revenue $204.6M, EPS $(0.39); Cuts 2026 Guidance
AI Summary
Inspire Medical Systems reported Q1 2026 financial results, with revenue increasing 1.6% to $204.6 million and a diluted EPS of $(0.39). The company achieved improved adjusted operating income and $12.8 million in operating cash flow. However, due to ongoing coding and reimbursement uncertainty and the WISeR program, Inspire revised its full-year 2026 revenue guidance downwards to $825 million-$875 million, representing a 4%-10% decline, and adjusted operating margin to 2%-4%.
Key Highlights
- Q1 2026 revenue increased 1.6% to $204.6 million.
- Q1 2026 diluted EPS was $(0.39); adjusted diluted EPS was $0.10.
- Q1 2026 operating cash flow was $12.8 million.
- Gross margin for Q1 2026 increased 180 bps to 86.5%.
- Full-year 2026 revenue guidance revised to $825M-$875M, a 4%-10% decline.
- Full-year 2026 adjusted operating margin guidance revised to 2%-4%.
- Full-year 2026 diluted EPS guidance revised to $0.07-$0.62 (GAAP) and $0.75-$1.25 (Adjusted).
- Challenges from coding and reimbursement uncertainty are expected to persist through 2026.
Price Impact
More from INSP